C von Schacky1. 1. Präventive Kardiologie, Medizinische Klinik I, Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336, München, Deutschland. clemens.vonschacky@med.uni-muenchen.de.
Abstract
BACKGROUND: Confusion reigns about omega‑3 fatty acids and their effects. Scientific investigations did not appear to clarify the issue. Guidelines and regulatory authorities contradict each other. OBJECTIVE: This article provides clarity by considering not intake but levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in erythrocytes as a percentage of all fatty acids measured (omega‑3 index). CURRENT DATA: The largest database of all methods of fatty acid analyses has been generated with the standardized HS-Omega‑3 Index® (Omegametrix, Martinsried, Deutschland). The omega‑3 index assesses the in EPA+DHA status of a person, has a minimum of 2%, a maximum of 20%, and is optimal between 8% and 11%. In many western countries but not in Japan or South Korea, mean levels are suboptimal. Suboptimal levels correlate with increased total mortality, sudden cardiac death, fatal and non-fatal myocardial infarction, other cardiovascular diseases, cognitive impairment, major depression, premature birth and other health issues. Interventional studies on surrogate and intermediary parameters demonstrated many positive effects, correlating with the omega‑3 index when measured. Due to issues in methodology that became apparent from the perspective of the omega‑3 index many, even large interventional trials with clinical endpoints were not positive, which is reflected in pertinent meta-analyses. In contrast, interventional trials without issues in methodology the clinical endpoints mentioned were reduced. CONCLUSION: All humans have levels of EPA+DHA that if methodologically correctly assessed in erythrocytes, are optimal between 8% and 11%. Deficits can cause serious health issues that can be prevented by optimal levels.
BACKGROUND: Confusion reigns about omega‑3 fatty acids and their effects. Scientific investigations did not appear to clarify the issue. Guidelines and regulatory authorities contradict each other. OBJECTIVE: This article provides clarity by considering not intake but levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in erythrocytes as a percentage of all fatty acids measured (omega‑3 index). CURRENT DATA: The largest database of all methods of fatty acid analyses has been generated with the standardized HS-Omega‑3 Index® (Omegametrix, Martinsried, Deutschland). The omega‑3 index assesses the in EPA+DHA status of a person, has a minimum of 2%, a maximum of 20%, and is optimal between 8% and 11%. In many western countries but not in Japan or South Korea, mean levels are suboptimal. Suboptimal levels correlate with increased total mortality, sudden cardiac death, fatal and non-fatal myocardial infarction, other cardiovascular diseases, cognitive impairment, major depression, premature birth and other health issues. Interventional studies on surrogate and intermediary parameters demonstrated many positive effects, correlating with the omega‑3 index when measured. Due to issues in methodology that became apparent from the perspective of the omega‑3 index many, even large interventional trials with clinical endpoints were not positive, which is reflected in pertinent meta-analyses. In contrast, interventional trials without issues in methodology the clinical endpoints mentioned were reduced. CONCLUSION: All humans have levels of EPA+DHA that if methodologically correctly assessed in erythrocytes, are optimal between 8% and 11%. Deficits can cause serious health issues that can be prevented by optimal levels.
Authors: Marcus E Kleber; Graciela E Delgado; Stefan Lorkowski; Winfried März; Clemens von Schacky Journal: Atherosclerosis Date: 2016-07-01 Impact factor: 5.162
Authors: Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno Journal: Eur Heart J Date: 2016-05-23 Impact factor: 29.983
Authors: Neville Jackson; Dan Atar; Maria Borentain; Günter Breithardt; Martin van Eickels; Matthias Endres; Uwe Fraass; Tim Friede; Hakima Hannachi; Salim Janmohamed; Jörg Kreuzer; Martin Landray; Dominik Lautsch; Chantal Le Floch; Peter Mol; Huseyin Naci; Nilesh J Samani; Anders Svensson; Cathrine Thorstensen; Jan Tijssen; Victoria Vandzhura; Andrew Zalewski; Paulus Kirchhof Journal: Eur Heart J Date: 2015-06-15 Impact factor: 29.983
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: S F Olsen; T I Halldorsson; A L Thorne-Lyman; M Strøm; S Gørtz; C Granstrøm; P H Nielsen; J Wohlfahrt; J A Lykke; J Langhoff-Roos; A S Cohen; J D Furtado; E L Giovannucci; W Zhou Journal: EBioMedicine Date: 2018-08-03 Impact factor: 8.143
Authors: Lichchavi D Rajasinghe; Quan-Zhen Li; Chengsong Zhu; Mei Yan; Preeti S Chauhan; Kathryn A Wierenga; Melissa A Bates; Jack R Harkema; Abby D Benninghoff; James J Pestka Journal: Autoimmunity Date: 2020-09-09 Impact factor: 2.957
Authors: Michael Berger; Florian Seemüller; Alessandra Voggt; Michael Obermeier; Franca Kirchberg; Anja Löw; Michael Riedel; Clemens von Schacky; Emanuel Severus Journal: Int J Bipolar Disord Date: 2022-04-01